Skip to content

Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO)

Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04510350
Acronym
CISCO
Enrollment
90
Registered
2020-08-12
Start date
2020-02-19
Completion date
2022-03-02
Last updated
2022-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

The objective of CISCO is therefore to identify prognostic biomarkers of MS activity in early-stage patients.

Interventions

Genetic analysis of regions of interest

Sponsors

Rennes University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Patients : Inclusion Criteria: * Patients with clinically isolated syndrome (CIS) participating in the OFSEP cohort (French MS Observatory) * At least 18 years of age * Diagnosed with MS according to criteria 2017 at the time of their last visit. * Non-opposition to participation in the study * Having had at least one visit in the year following collection * Follow-up for at least 1 year after collection. * Having signed the OFSEP consent

Exclusion criteria

* CIS patients with progressive MS Healthy volunteers : Inclusion Criteria: * Age 18 years or older * Having participated in the ABCD-SEP clinical trial promoted by the Rennes University Hospital (NCT03744351). * Matched on age and sex to patients of interest in the OFSEP cohort * Not having objected to participation in the study

Design outcomes

Primary

MeasureTime frameDescription
Frequency of immune subpopulations1 yearCorrelations between the frequency of immune subpopulations, genetic profile and disease activity

Secondary

MeasureTime frameDescription
Frequency of immune subpopulations correlated to EDSS score1 yearCorrelations between the frequency of immune subpopulations, genetic profile, and EDSS score ((Expanded Disability Status Scale, method of quantifying disability in multiple sclerosis, steps 1.0 to 4.5 refer to people with MS who are fully ambulatory. EDSS steps 5.0 to 9.5 are defined by the impairment to ambulation.)
Frequency of immune subpopulations correlated to disease progression delay1 yearCorrelations between the frequency of immune subpopulations, genetic profile, and delay before disease progression
Frequency of immune subpopulations correlated to disease progression events1 yearCorrelations between the frequency of immune subpopulations, genetic profile, and number of disease progression events
Frequency of immune subpopulations correlated to spinal lesions1 yearCorrelations between the frequency of immune subpopulations, genetic profile, and number of new spinal lesions
Profiles of CIS+ patients1 yearComparison of genetic and immunological profiles of CIS+ patients with healthy volunteers

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026